Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
复制标题
纳武单抗 (Nivo) 伊匹单抗 (Ipi) 与铂类双药化疗 (Chemo) 作为晚期非小细胞肺癌 (NSCLC) 一线 (1L) 治疗 (Tx)：安全性分析和患者报告结果 (PRO)
DOI：
10.1200/jco.2018.36.15_suppl.9020
复制
发表时间：
2018
影响因子：
45.3
通讯作者：
H. Borghaei
中科院分区：
文献类型：
--
作者：
M. Reck;M. Hellmann;L. Paz;S. Ramalingam;J. Brahmer;K. O'Byrne;P. Bhagavatheeswaran;F. Nathan;H. Borghaei
9020背景：Checkmate 227(NCT02477826)是一项大型的3期研究，研究了1L Nivo+ipi、Nivo或Nivo+化疗与化疗在晚期非小细胞肺癌中的作用。这项研究达到了共同的主要终点，表明了重要的...
9020Background: CheckMate 227 (NCT02477826) is a large phase 3 study of 1L nivo + ipi, nivo, or nivo + chemo vs chemo in advanced NSCLC. The study met its co-primary endpoint demonstrating signific...